drugset / Trial / NCT03815682
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
Timeline
- Start
- 2018-10-24
- Primary completion
- 2022-09-07
- Completion
- 2022-10-11
Outcome
Outcome not reported
Stopped: “Development program terminated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | RPTR-147:1 | Cell therapy | — | — |
| Subject | RPTR-147:2 | Cell therapy | — | — |